Gufic Q2: consolidated PAT +40% YoY to ₹23.5 Cr, revenue +22%, but misses ₹35-42 Cr bar
PAT +39.51% YoY · revenue +21.6% · margins expanding · miss vs street
₹288.27 Cr
+21.6% YoY
₹23.47 Cr
+39.51% YoY
8.11%
+1.1pp YoY
₹2.34
Gufic's consolidated revenue came in at ₹288.27 Cr, up 21.6% YoY and 10.5% QoQ, while consolidated PAT rose 39.5% YoY to ₹23.47 Cr but grew just 5.2% QoQ from ₹22.31 Cr — a clear sequential slowdown in profit growth even as the topline accelerated. Standalone PAT of ₹23.49 Cr grew a faster 57.2% YoY (from ₹14.94 Cr a year ago), a meaningfully wider gap than the consolidated 39.5% YoY print: a year ago the foreign/CMO subsidiaries (Gufic UK, Veira Life FZE, Gufic Ireland, Gufic Prime) added roughly ₹2 Cr of incremental profit over standalone, but this quarter their net contribution to the group turned marginally negative versus standalone — the subsidiaries that boosted consolidated growth last year are now a mild drag on it.
Q2 FY-2027 vs prior quarters
Operating margin expanded YoY to 16.82% from 15.97%, and net margin to 8.11% from 7.03%, but both compressed sequentially from Q1's 17.87% OPM / 8.54% NPM. The QoQ squeeze traces to cost of materials consumed jumping 47.9% QoQ (₹156.92 Cr vs ₹106.14 Cr) against only 10.5% QoQ revenue growth — materials cost outran the topline this quarter even though the YoY margin comparison still looks favourable against a weaker year-ago base.
The stock went into the print at ₹473.05, up 13.6% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
FY27 full-year revenue ₹1,100 Cr baseline with 15% growth potential reaching ₹1,250-1,600 Cr. EBITDA margins ~18% in FY27, targeting >20% by 2030 through Indore utilization (40-45% by year-end), CMO ramp-up (30% domestic, 70% international mix), and product mix improvement. Capex ~₹300 Cr absorbed.
— This quarter: met
No formal analyst consensus for this specific quarter turned up in a search, so the cleanest expectation check is our own pre-result preview: it flagged revenue of ~₹260-280 Cr and PAT of ₹35-42 Cr. Actual revenue (₹288.27 Cr) cleared that range, but PAT (₹23.47 Cr) missed the low end by roughly a third — a beat on the top line paired with a sizeable miss on profitability. Against management's standing FY27 guidance (₹1,100 Cr baseline revenue with 15% upside to ₹1,250-1,600 Cr, ~18% operating margin), H1 FY27 consolidated revenue of ₹550.67 Cr annualises to ~₹1,101 Cr — right on the baseline but showing no sign yet of the double-digit upside case — while H1 OPM of 17.32% (and this quarter's 16.82%) still trails the ~18% target, with the Indore capacity ramp management has cited as the lever to close that gap not yet fully reflected. No company press release was available in our records to cross-check management's own framing of the quarter.
W1
H2 FY27 margin trajectory — can OPM recover toward management's ~18% FY27 target as Indore utilization ramps toward the flagged 40-45% by year-end?
W2
Remediation/resolution of the 3 USFDA observations from the Oct 15-23 pre-approval inspection, and its bearing on the flagged product's US approval timeline
W3
Whether H2 revenue accelerates enough to move beyond the ₹1,100 Cr FY27 baseline run-rate toward management's ₹1,250-1,600 Cr upside case
Text-based filing, clean column headers (Standalone+Consolidated x Q2/Q1/Q2-ago/H1/H1-ago/FY); no exceptional items in current or comparison periods; minority interest negligible (₹0.03 Lakh); figures converted from Rs. Lakhs to Rs. Crore (÷100). Consolidated PAT uses 'net profit from continuing operations' line (pre-minority) for consistency with comparison-context figures.
Informational and educational content only. Not investment advice.